tarlatamab
Selected indexed studies
- Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer. (N Engl J Med, 2023) [PMID:37861218]
- Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. (J Clin Oncol, 2023) [PMID:36689692]
- Tarlatamab: First Approval. (Drugs, 2024) [PMID:39023700]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer. (2023) pubmed
- Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. (2023) pubmed
- Tarlatamab: First Approval. (2024) pubmed
- Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy. (2025) pubmed
- Tarlatamab. (2006) pubmed
- Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer. (2025) pubmed
- Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study. (2025) pubmed
- Plain language summary: tarlatamab for patients with previously treated small cell lung cancer. (2024) pubmed
- Tarlatamab for small-cell lung cancer. (2025) pubmed
- Tarlatamab-dlle: A New Hope for Patients with Extensive-Stage Small-Cell Lung Cancer. (2024) pubmed